Poziotinib

Generic Name: Poziotinib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₁Cl_₂FN_₄O_₃

CAS Number: 1092364-38-9

Unique Ingredient Identifier: OEI6OOU6IK

Background: Poziotinib has been used in trials studying the treatment of Breast Cancer, Metastatic Breast Cancer, Increased Drug Resistance, Adenocarcinoma of Lung Stage IV, and Adenocarcinoma of Lung Stage IIIB, among others.

Indication: 用于治疗非小细胞肺癌、乳腺癌和胃癌。对于吉非替尼和厄洛替尼耐药性EGFR L858R/T790M双突变细胞有很强的抑制作用。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

HER2-mutant Non-Small Cell Lung Cancer Clinical Trials

DelveInsight's 'HER2-mutant Non-Small Cell Lung Cancer Pipeline Insight 2024' covers 5+ companies and 5+ pipeline drugs, including clinical and nonclinical profiles, therapeutic assessments by product type, stage, route of administration, and molecule type, highlighting inactive products. Key companies include Dizal Pharmaceuticals, Puma Biotechnology, AstraZeneca, Jiangsu Hengrui Medicine, and Spectrum Pharmaceuticals Inc., with promising therapies like Trastuzumab deruxtecan and Poziotinib.

Related Clinical Trials:

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer with EGFR or HER2 Mutation (WU-KONG1)

A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer

A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy